The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 10, 2023

Filed:

Aug. 07, 2020
Applicants:

Suzhou Suncadia Biopharmaceuticals Co., Ltd., Jiangsu, CN;

Jiangsu Hengrui Medicine Co., Ltd., Jiangsu, CN;

Shanghai Hengrui Pharmaceutical Co., Ltd., Shanghai, CN;

Inventors:

Xiangdong Qu, Shanghai, CN;

Qiyue Hu, Shanghai, CN;

Shaoyu Xu, Shanghai, CN;

Dongbing Cui, Shanghai, CN;

Houcong Jin, Shanghai, CN;

Weikang Tao, Shanghai, CN;

Lianshan Zhang, Shanghai, CN;

Guoqing Cao, Shanghai, CN;

Piaoyang Sun, Jiangsu, CN;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2827 (2013.01); A61K 39/395 (2013.01); A61P 35/00 (2018.01); C07K 16/28 (2013.01); A61K 2039/505 (2013.01); A61K 2039/572 (2013.01); C07K 2317/24 (2013.01); C07K 2317/40 (2013.01); C07K 2317/52 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); C07K 2317/732 (2013.01); C07K 2317/734 (2013.01); C07K 2317/92 (2013.01);
Abstract

The present invention relates to a PD-L1 antibody, antigen-binding fragments, and medical application thereof. Further, the present invention relates to chimeric antibodies and humanized antibodies comprising the CDR regions of the present PD-L1 antibody, as well as a pharmaceutical composition comprising the present PD-L1 antibody and the antigen-binding fragments thereof, and their use as anti-cancer drugs. In particular, the present invention relates to a humanized PD-L1 antibody and its use in preparation of a medicament for the treatment of PD-L1 mediated disease or disorder.


Find Patent Forward Citations

Loading…